Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Hilleman DE, Wiggins BS, Bottorff MB. A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review.” Adv Ther. 2020; epub ahead of print.

https://link.springer.com/article/10.1007/s12325-020-01420-z

Boden WE, Bhatt DL, Toth PP, et al. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. Eur Heart J. 2020;41(24):2304–2312.

https://doi.org/10.1093/eurheartj/ehz778
Sherratt S, Bhatt D, Mason P. Eicosapentaenoic acid inhibits membrane cholesterol domains compared to other omega-3 fatty acids under conditions of hyperglycemia [abstract 005]. Can J Cardiol. 2020;36(10 suppl):S2-S3. https://www.onlinecjc.ca/article/S0828-282X(20)30644-9/fulltext
Eicosapentaenoic acid, but not a mixed omega-3 fatty acid supplement, improved nitric oxide bioavailability in human endothelial cells in vitro.
Mason RP, Dawoud H, Sherratt SCR, Malinski T. Eicosapentaenoic acid, but not a mixed omega-3 fatty acid supplement, improved nitric oxide bioavailability in human endothelial cells in vitro. Presented at the European Atherosclerosis Society meeting, October 4-7, 2020 (virtual).
Managing the lipid triad: improving physicians' understanding of the role of omega-3 fatty acids with CME
Larkin AT, Healy CS. Managing the lipid triad: improving physicians' understanding of the role of omega-3 fatty acids with CME [abstract 177]. J Clin Lipidol. 2015;9:466-7.

Amarin Corporation